Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma

ClinicalTrials.gov ID: NCT03421730

Public ClinicalTrials.gov record NCT03421730. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-dose, Open-label, Randomized, Incomplete Block Design Trial to Characterize the Pharmacokinetics of VR647 Inhalation Suspension Delivered by the VR647 Inhalation System and Single Doses of Budesonide Delivered by a Conventional Jet Nebulizer in Pediatric Subjects Aged 4 to 8 Years With Wheezing, Reactive Airway Disease or Mild Asthma

Study identification

NCT ID
NCT03421730
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Vectura Limited
Industry
Enrollment
17 participants

Conditions and interventions

Interventions

  • VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System Combination Product
  • 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer Combination Product

Combination Product

Eligibility (public fields only)

Age range
4 Years to 8 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 17, 2017
Primary completion
Mar 20, 2018
Completion
Mar 26, 2018
Last update posted
Oct 20, 2019

2017 – 2018

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Vectura Study Site 0003 Colorado Springs Colorado 80907
Vectura Study Site 0002 Raleigh North Carolina 27607
Vectura Study Site 0001 Tulsa Oklahoma 74136

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03421730, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2019 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03421730 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →